Skip to main content
SpringerLink
Log in

Drug-Excipient Incompatibility Studies of the Dipeptide Angiotensin-Converting Enzyme Inhibitor, Moexipril Hydrochloride: Dry Powder vs Wet Granulation

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The drug-excipient incompatibility screen for moexipril hydrochloride (1) using various isothermal stress methods is reported herein. It was found that most of the commonly used fillers, disintegrants, lubricants, glidants, and coating agents were incompatible with 1 in dry powder mixtures; moisture and basic (or alkalizing) agents were determined to be the dominant destabilizing factors. In wet granulations, basic agents, however, were found to suppress drug degradation even in the presence of moisture. Supported by the product distribution studies, the stabilization is proposed to involve the neutralization of the acidic drug by the basic excipients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. D. C. Monkhouse and J. L. Lach. Can. J. Pharm. Sci. 7:29–46 (1972).

    Google Scholar 

  2. J. T. Carstensen. J. Pharm. Sci. 63:1–14 (1974).

    Google Scholar 

  3. H. H. El-Shattawy, D. O. Kildsig, and G. E. Peck. Drug Dev. Ind. Pharm. 8:923–935 (1982).

    Google Scholar 

  4. H. H. El Shattawy. Drug Dev. Ind. Pharm. 8:819–831 (1982).

    Google Scholar 

  5. E. C. Signoretti, A. Dell'Utric, A. D. Salvo, and L. Donini. Drug Dev. Ind. Pharm. 12:603–620 (1986).

    Google Scholar 

  6. A. A. Van Dooren. Drug Dev. Ind. Pharm. 9:43–55 (1983).

    Google Scholar 

  7. F. A. Chrzanowski, L. A. Ullissi, B. J. Fegely, and A. C. Newman. Drug Dev. Ind. Pharm. 12:783–800 (1986).

    Google Scholar 

  8. M. J. Wyvratt and A. A. Patchett. Med. Res. Rev. 5:485–531 (1985).

    Google Scholar 

  9. P. K. Shiromani and J. F. Bwitz. Drug Dev. Ind. Pharm. 12:2467–2480 (1986).

    Google Scholar 

  10. M. L. Cotton, D. W. Wu, and E. B. Vadas. Inst. J. Pharm. 40:129–142 (1987).

    Google Scholar 

  11. L. Gu and R. G. Strickley. Pharm. Res. 4:392–397 (1987).

    Google Scholar 

  12. L. Gu and R. G. Strickley. Pharm. Res. 5:765–771 (1988).

    Google Scholar 

  13. R. E. Bouvette and G. A. Digenis. Pharm. Res. 4:5–35 (1987).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmaceutical Sciences, Syntex Research, Palo Alto, California, 94304

    Leo Gu, Robert G. Strickley, Li-Hua Chi & Zak T. Chowhan

Authors
  1. Leo Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert G. Strickley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-Hua Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zak T. Chowhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gu, L., Strickley, R.G., Chi, LH. et al. Drug-Excipient Incompatibility Studies of the Dipeptide Angiotensin-Converting Enzyme Inhibitor, Moexipril Hydrochloride: Dry Powder vs Wet Granulation. Pharm Res 7, 379–383 (1990). https://doi.org/10.1023/A:1015871406549

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015871406549

Search

Navigation